DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Market Closed - Börse Stuttgart 11:59:39 2024-05-31 EDT | ||
| 0.61 EUR | +3.39% |
|
| 1 month | -3.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 0.61 | +3.39% |
| 24-05-30 | 0.59 | -1.67% |
| 24-05-29 | 0.6 | -1.64% |
| 24-05-28 | 0.61 | -.--% |
| 24-05-27 | 0.61 | -4.69% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 11:59 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0D7R |
| ISIN | DE000MG0D7R2 |
| Date issued | 2024-03-18 |
| Strike | 450 $ |
| Maturity | 2025-03-21 (292 Days) |
| Parity | 10 : 1 |
| Emission price | 0.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.96 € |
|---|---|
| Lowest since issue | 0.43 € |
| Spread | 0.05 € |
| Spread % | 7.35% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
236.2
USD
Average target price
363.9
USD
Spread / Average Target
+54.07%
- Stock Market
- Certificates
- Certificat
